Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This phase I, open-label, dose-escalation study was conducted to determine the maximum
tolerated dose (MTD), recommended phase II dose (RP2D), dose-limiting toxicities (DLTs),
pharmacokinetics (PK) profile, and preliminary antitumor activity of single and multiple
doses of PLB1001 in Patients with PTPRZ1-MET fusion gene positive recurrent high-grade
Gliomas.
Phase:
Phase 1
Details
Lead Sponsor:
Beijing Pearl Biotechnology Limited Liability Company